| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Prescriptions | 54 | 2015 | 1667 | 3.270 |
Why?
|
| Medicare Part D | 18 | 2021 | 355 | 3.090 |
Why?
|
| Deductibles and Coinsurance | 29 | 2022 | 315 | 2.570 |
Why?
|
| Drug Utilization | 58 | 2013 | 1190 | 2.340 |
Why?
|
| Insurance, Pharmaceutical Services | 25 | 2013 | 348 | 2.320 |
Why?
|
| Medicaid | 47 | 2017 | 2840 | 2.190 |
Why?
|
| Health Maintenance Organizations | 32 | 2016 | 656 | 1.950 |
Why?
|
| Drug Utilization Review | 14 | 2011 | 248 | 1.940 |
Why?
|
| Antidepressive Agents | 18 | 2024 | 2913 | 1.860 |
Why?
|
| Comparative Effectiveness Research | 5 | 2019 | 714 | 1.780 |
Why?
|
| United States Food and Drug Administration | 11 | 2024 | 1671 | 1.710 |
Why?
|
| Prescription Fees | 10 | 2014 | 153 | 1.680 |
Why?
|
| Drug Costs | 27 | 2021 | 1195 | 1.610 |
Why?
|
| Benzodiazepines | 13 | 2024 | 1138 | 1.600 |
Why?
|
| Mass Media | 7 | 2014 | 303 | 1.450 |
Why?
|
| Cost Sharing | 20 | 2021 | 409 | 1.380 |
Why?
|
| Drug Labeling | 8 | 2024 | 250 | 1.290 |
Why?
|
| Treatment Refusal | 8 | 2013 | 433 | 1.280 |
Why?
|
| Financing, Personal | 12 | 2020 | 310 | 1.220 |
Why?
|
| Drug Therapy | 13 | 2008 | 504 | 1.210 |
Why?
|
| Medicare | 27 | 2021 | 6809 | 1.130 |
Why?
|
| Medication Adherence | 10 | 2021 | 2187 | 1.070 |
Why?
|
| Product Surveillance, Postmarketing | 6 | 2014 | 463 | 1.060 |
Why?
|
| Health Services Research | 16 | 2016 | 1815 | 1.000 |
Why?
|
| Education, Medical, Continuing | 18 | 2007 | 829 | 0.970 |
Why?
|
| Insurance Coverage | 15 | 2018 | 1946 | 0.950 |
Why?
|
| Patient Compliance | 18 | 2010 | 2697 | 0.940 |
Why?
|
| Health Policy | 22 | 2018 | 2698 | 0.920 |
Why?
|
| Clinical Pharmacy Information Systems | 6 | 2006 | 102 | 0.910 |
Why?
|
| Bipolar Disorder | 11 | 2022 | 5130 | 0.910 |
Why?
|
| Reimbursement, Incentive | 7 | 2016 | 541 | 0.900 |
Why?
|
| Research Design | 18 | 2018 | 6211 | 0.870 |
Why?
|
| Antipsychotic Agents | 10 | 2022 | 3081 | 0.840 |
Why?
|
| Disabled Persons | 8 | 2021 | 1210 | 0.810 |
Why?
|
| Health Services | 5 | 2013 | 755 | 0.750 |
Why?
|
| Suicide | 4 | 2024 | 1606 | 0.750 |
Why?
|
| Psychotropic Drugs | 9 | 2015 | 881 | 0.750 |
Why?
|
| United States | 114 | 2024 | 73027 | 0.710 |
Why?
|
| State Health Plans | 10 | 2013 | 220 | 0.700 |
Why?
|
| Reimbursement Mechanisms | 8 | 2011 | 670 | 0.660 |
Why?
|
| Quality Assurance, Health Care | 10 | 2016 | 2175 | 0.640 |
Why?
|
| Poverty | 10 | 2020 | 2720 | 0.590 |
Why?
|
| Schizophrenia | 8 | 2015 | 6983 | 0.580 |
Why?
|
| Leukotriene Antagonists | 2 | 2015 | 124 | 0.580 |
Why?
|
| Health Expenditures | 17 | 2022 | 2389 | 0.560 |
Why?
|
| Reminder Systems | 4 | 2009 | 388 | 0.550 |
Why?
|
| Quality of Health Care | 15 | 2011 | 4310 | 0.550 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2008 | 1243 | 0.540 |
Why?
|
| Electronic Health Records | 5 | 2016 | 4884 | 0.540 |
Why?
|
| Fees, Pharmaceutical | 5 | 2011 | 66 | 0.540 |
Why?
|
| Legislation, Drug | 5 | 2010 | 216 | 0.530 |
Why?
|
| Humans | 271 | 2024 | 767991 | 0.510 |
Why?
|
| Suicide, Attempted | 4 | 2024 | 1413 | 0.510 |
Why?
|
| Insurance, Health | 13 | 2020 | 2517 | 0.500 |
Why?
|
| Gatekeeping | 4 | 2010 | 49 | 0.500 |
Why?
|
| Antihypertensive Agents | 7 | 2017 | 2029 | 0.490 |
Why?
|
| Ambulatory Care | 8 | 2017 | 2781 | 0.490 |
Why?
|
| Anti-Anxiety Agents | 4 | 2010 | 405 | 0.480 |
Why?
|
| Medical Indigency | 4 | 2011 | 63 | 0.480 |
Why?
|
| Guideline Adherence | 16 | 2014 | 2235 | 0.470 |
Why?
|
| Formularies as Topic | 7 | 2009 | 94 | 0.460 |
Why?
|
| Anticonvulsants | 4 | 2012 | 1922 | 0.450 |
Why?
|
| Myocardial Infarction | 15 | 2008 | 11519 | 0.450 |
Why?
|
| Histamine H2 Antagonists | 3 | 2005 | 169 | 0.440 |
Why?
|
| Mental Disorders | 9 | 2016 | 6875 | 0.440 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2015 | 347 | 0.430 |
Why?
|
| Aged | 105 | 2021 | 171446 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2016 | 10396 | 0.430 |
Why?
|
| Female | 153 | 2021 | 397113 | 0.420 |
Why?
|
| Male | 144 | 2021 | 364641 | 0.420 |
Why?
|
| Marketing | 2 | 2012 | 224 | 0.410 |
Why?
|
| Community Mental Health Centers | 2 | 2011 | 93 | 0.410 |
Why?
|
| Medical Staff, Hospital | 5 | 2006 | 602 | 0.400 |
Why?
|
| Diabetes Mellitus | 13 | 2020 | 5887 | 0.400 |
Why?
|
| Clinical Coding | 1 | 2014 | 188 | 0.400 |
Why?
|
| Middle Aged | 103 | 2021 | 223422 | 0.400 |
Why?
|
| Medically Uninsured | 2 | 2020 | 840 | 0.390 |
Why?
|
| Primary Health Care | 14 | 2015 | 4746 | 0.390 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2015 | 572 | 0.390 |
Why?
|
| Chronic Disease | 13 | 2021 | 9384 | 0.390 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2012 | 139 | 0.380 |
Why?
|
| Drug Monitoring | 2 | 2009 | 964 | 0.380 |
Why?
|
| Cost Control | 17 | 2010 | 627 | 0.380 |
Why?
|
| Cost of Illness | 4 | 2013 | 1951 | 0.380 |
Why?
|
| Hypolipidemic Agents | 4 | 2017 | 609 | 0.370 |
Why?
|
| Child Behavior Disorders | 2 | 2016 | 812 | 0.370 |
Why?
|
| Drug Industry | 6 | 2012 | 791 | 0.370 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2007 | 1515 | 0.370 |
Why?
|
| Cluster Analysis | 3 | 2014 | 2731 | 0.370 |
Why?
|
| Amines | 1 | 2012 | 280 | 0.360 |
Why?
|
| Emergency Service, Hospital | 12 | 2018 | 7939 | 0.360 |
Why?
|
| Medication Errors | 3 | 2006 | 784 | 0.360 |
Why?
|
| Managed Care Programs | 6 | 2008 | 939 | 0.360 |
Why?
|
| Off-Label Use | 1 | 2012 | 185 | 0.360 |
Why?
|
| Catheter-Related Infections | 4 | 2015 | 275 | 0.360 |
Why?
|
| Calcium Channel Blockers | 5 | 2003 | 688 | 0.350 |
Why?
|
| Economics, Hospital | 5 | 2015 | 208 | 0.350 |
Why?
|
| Program Evaluation | 8 | 2015 | 2506 | 0.340 |
Why?
|
| Medical Records | 7 | 2011 | 1409 | 0.340 |
Why?
|
| New Jersey | 11 | 2011 | 296 | 0.340 |
Why?
|
| Access to Information | 1 | 2013 | 317 | 0.340 |
Why?
|
| Hospitalization | 13 | 2018 | 10840 | 0.330 |
Why?
|
| Emergencies | 1 | 2016 | 1224 | 0.330 |
Why?
|
| Warfarin | 4 | 2008 | 1493 | 0.330 |
Why?
|
| New Hampshire | 9 | 2010 | 174 | 0.330 |
Why?
|
| Efficiency, Organizational | 2 | 2012 | 697 | 0.320 |
Why?
|
| Polypharmacy | 4 | 2014 | 307 | 0.320 |
Why?
|
| Fast Foods | 1 | 2011 | 219 | 0.320 |
Why?
|
| Pregnadienediols | 1 | 2008 | 9 | 0.320 |
Why?
|
| Health Care Costs | 10 | 2020 | 3239 | 0.310 |
Why?
|
| Food Labeling | 1 | 2011 | 181 | 0.310 |
Why?
|
| Nursing Homes | 10 | 2010 | 1084 | 0.310 |
Why?
|
| Government Programs | 1 | 2011 | 278 | 0.310 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 1395 | 0.310 |
Why?
|
| Benchmarking | 1 | 2015 | 1057 | 0.310 |
Why?
|
| Mental Health Services | 5 | 2016 | 1733 | 0.310 |
Why?
|
| Adult | 81 | 2021 | 223583 | 0.300 |
Why?
|
| Cross Infection | 5 | 2015 | 1426 | 0.300 |
Why?
|
| Hip Fractures | 4 | 2015 | 997 | 0.300 |
Why?
|
| Pharmaceutical Services | 2 | 2008 | 143 | 0.300 |
Why?
|
| Socioeconomic Factors | 16 | 2016 | 7851 | 0.290 |
Why?
|
| Drug Information Services | 8 | 2012 | 51 | 0.290 |
Why?
|
| Depression | 6 | 2024 | 8231 | 0.290 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2007 | 475 | 0.290 |
Why?
|
| Depressive Disorder | 4 | 2009 | 3721 | 0.290 |
Why?
|
| Health Benefit Plans, Employee | 3 | 2017 | 332 | 0.280 |
Why?
|
| Internet | 2 | 2013 | 3110 | 0.280 |
Why?
|
| Adolescent | 42 | 2024 | 89155 | 0.280 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2009 | 746 | 0.270 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2015 | 1883 | 0.270 |
Why?
|
| Insurance Claim Review | 12 | 2016 | 743 | 0.270 |
Why?
|
| Maine | 4 | 2011 | 146 | 0.260 |
Why?
|
| Health Status | 5 | 2015 | 4092 | 0.260 |
Why?
|
| Drug Approval | 6 | 2014 | 820 | 0.260 |
Why?
|
| Pediatrics | 6 | 2015 | 3629 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 15 | 2015 | 5536 | 0.260 |
Why?
|
| Hypoglycemic Agents | 8 | 2020 | 3108 | 0.260 |
Why?
|
| Heart Arrest | 1 | 2016 | 1516 | 0.260 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1140 | 0.260 |
Why?
|
| Thrombolytic Therapy | 6 | 2002 | 2055 | 0.260 |
Why?
|
| Data Interpretation, Statistical | 3 | 2014 | 2708 | 0.260 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2006 | 1178 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 587 | 0.260 |
Why?
|
| Mass Screening | 5 | 2016 | 5458 | 0.260 |
Why?
|
| Patient Education as Topic | 7 | 2008 | 2336 | 0.250 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 59598 | 0.250 |
Why?
|
| Prescription Drugs | 1 | 2013 | 635 | 0.250 |
Why?
|
| Social Marketing | 1 | 2005 | 52 | 0.250 |
Why?
|
| Prescriptions | 3 | 2024 | 388 | 0.250 |
Why?
|
| Medical Audit | 7 | 2009 | 454 | 0.250 |
Why?
|
| Asthma | 7 | 2016 | 6273 | 0.250 |
Why?
|
| Anti-Infective Agents | 2 | 2006 | 983 | 0.250 |
Why?
|
| Clinical Competence | 5 | 2006 | 4857 | 0.240 |
Why?
|
| Longitudinal Studies | 20 | 2020 | 14783 | 0.240 |
Why?
|
| Self Administration | 2 | 2006 | 386 | 0.240 |
Why?
|
| Fee-for-Service Plans | 5 | 2017 | 713 | 0.240 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 145 | 0.240 |
Why?
|
| Dyspepsia | 2 | 2005 | 116 | 0.240 |
Why?
|
| Young Adult | 21 | 2024 | 60048 | 0.240 |
Why?
|
| Health Care Reform | 4 | 2016 | 1256 | 0.230 |
Why?
|
| Antiparkinson Agents | 1 | 2005 | 184 | 0.230 |
Why?
|
| Helicobacter pylori | 2 | 2005 | 380 | 0.230 |
Why?
|
| Helicobacter Infections | 2 | 2005 | 390 | 0.220 |
Why?
|
| Medical Savings Accounts | 2 | 2022 | 34 | 0.220 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 319 | 0.220 |
Why?
|
| Energy Intake | 1 | 2011 | 2145 | 0.220 |
Why?
|
| Hypertension | 7 | 2011 | 8616 | 0.220 |
Why?
|
| Regression Analysis | 12 | 2015 | 6339 | 0.220 |
Why?
|
| New York | 6 | 2007 | 882 | 0.220 |
Why?
|
| Dihydropyridines | 2 | 2003 | 67 | 0.220 |
Why?
|
| Logistic Models | 16 | 2015 | 13289 | 0.210 |
Why?
|
| Ramipril | 1 | 2003 | 102 | 0.210 |
Why?
|
| Massachusetts | 25 | 2016 | 8888 | 0.210 |
Why?
|
| Policy Making | 3 | 2015 | 546 | 0.210 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 1381 | 0.210 |
Why?
|
| Consumer Product Safety | 2 | 2014 | 122 | 0.210 |
Why?
|
| Hospitals | 11 | 2015 | 3886 | 0.210 |
Why?
|
| Total Quality Management | 2 | 2003 | 265 | 0.210 |
Why?
|
| Health Services Accessibility | 11 | 2017 | 5520 | 0.200 |
Why?
|
| Cohort Studies | 30 | 2018 | 41749 | 0.200 |
Why?
|
| Anticoagulants | 4 | 2008 | 4854 | 0.200 |
Why?
|
| Health Priorities | 1 | 2005 | 380 | 0.200 |
Why?
|
| Rate Setting and Review | 1 | 2002 | 41 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2020 | 3231 | 0.200 |
Why?
|
| British Columbia | 7 | 2004 | 240 | 0.200 |
Why?
|
| Attitude of Health Personnel | 6 | 2012 | 3929 | 0.200 |
Why?
|
| Diuretics | 1 | 2005 | 614 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 3 | 2007 | 1086 | 0.190 |
Why?
|
| Blood Transfusion | 3 | 1993 | 1308 | 0.190 |
Why?
|
| Child | 34 | 2024 | 80906 | 0.190 |
Why?
|
| Community Pharmacy Services | 2 | 2003 | 52 | 0.190 |
Why?
|
| Telephone | 3 | 2010 | 630 | 0.180 |
Why?
|
| Family Practice | 6 | 2013 | 509 | 0.180 |
Why?
|
| Health Services Misuse | 4 | 1996 | 246 | 0.180 |
Why?
|
| Endpoint Determination | 2 | 2014 | 592 | 0.180 |
Why?
|
| Homes for the Aged | 4 | 2010 | 273 | 0.180 |
Why?
|
| Age Factors | 11 | 2014 | 18407 | 0.180 |
Why?
|
| Child Health Services | 2 | 2016 | 645 | 0.170 |
Why?
|
| Indoles | 1 | 2008 | 1835 | 0.170 |
Why?
|
| Physicians | 6 | 2017 | 4598 | 0.170 |
Why?
|
| Health Surveys | 5 | 2018 | 4056 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2014 | 8082 | 0.170 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2016 | 1196 | 0.170 |
Why?
|
| Minnesota | 6 | 2000 | 339 | 0.170 |
Why?
|
| Spironolactone | 1 | 2003 | 415 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 551 | 0.170 |
Why?
|
| Journalism, Medical | 1 | 2000 | 73 | 0.170 |
Why?
|
| Pharmacy Administration | 1 | 1999 | 3 | 0.170 |
Why?
|
| Speech Recognition Software | 2 | 2010 | 74 | 0.170 |
Why?
|
| Aspirin | 10 | 2001 | 3135 | 0.160 |
Why?
|
| Patient Care | 1 | 2005 | 629 | 0.160 |
Why?
|
| Government Regulation | 2 | 2014 | 525 | 0.160 |
Why?
|
| Organizational Policy | 3 | 2011 | 435 | 0.160 |
Why?
|
| Confidence Intervals | 5 | 2010 | 2923 | 0.160 |
Why?
|
| Medical Staff | 2 | 2004 | 40 | 0.160 |
Why?
|
| Prevalence | 11 | 2021 | 15867 | 0.160 |
Why?
|
| Vulnerable Populations | 3 | 2019 | 718 | 0.160 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1993 | 134 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 13 | 2015 | 7445 | 0.150 |
Why?
|
| Hyperlipidemias | 3 | 2011 | 772 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2007 | 3701 | 0.150 |
Why?
|
| Eligibility Determination | 4 | 2017 | 421 | 0.150 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 467 | 0.150 |
Why?
|
| Time Factors | 18 | 2018 | 40214 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2271 | 0.140 |
Why?
|
| Income | 5 | 2019 | 1878 | 0.140 |
Why?
|
| New England | 7 | 2011 | 1058 | 0.140 |
Why?
|
| Interviews as Topic | 6 | 2007 | 2741 | 0.140 |
Why?
|
| Selection Bias | 2 | 2015 | 360 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 3781 | 0.140 |
Why?
|
| Chlorofluorocarbons | 1 | 2016 | 12 | 0.140 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 12075 | 0.140 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 198 | 0.140 |
Why?
|
| Retrospective Studies | 29 | 2020 | 81746 | 0.140 |
Why?
|
| Missouri | 1 | 2016 | 113 | 0.140 |
Why?
|
| Diarrhea, Infantile | 1 | 1996 | 100 | 0.130 |
Why?
|
| Family Health | 2 | 2012 | 1255 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 4564 | 0.130 |
Why?
|
| South Carolina | 1 | 2016 | 113 | 0.130 |
Why?
|
| Suicidal Ideation | 2 | 2024 | 1467 | 0.130 |
Why?
|
| Specialization | 1 | 2001 | 779 | 0.130 |
Why?
|
| Cardiology Service, Hospital | 1 | 1998 | 242 | 0.130 |
Why?
|
| Pharmacies | 2 | 2009 | 171 | 0.130 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 2663 | 0.130 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 139 | 0.130 |
Why?
|
| Proportional Hazards Models | 7 | 2011 | 12536 | 0.130 |
Why?
|
| Albuterol | 1 | 2016 | 211 | 0.130 |
Why?
|
| Breast Neoplasms | 7 | 2019 | 21206 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 12252 | 0.130 |
Why?
|
| Social Desirability | 1 | 2015 | 45 | 0.130 |
Why?
|
| Indiana | 3 | 2011 | 93 | 0.120 |
Why?
|
| Health Education | 4 | 2008 | 1059 | 0.120 |
Why?
|
| Truth Disclosure | 2 | 2015 | 434 | 0.120 |
Why?
|
| Administrative Personnel | 1 | 2016 | 185 | 0.120 |
Why?
|
| Safety Management | 2 | 2015 | 765 | 0.120 |
Why?
|
| Postnatal Care | 4 | 2011 | 273 | 0.120 |
Why?
|
| Health Care Surveys | 5 | 2018 | 2433 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 20218 | 0.120 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 3837 | 0.120 |
Why?
|
| Michigan | 3 | 2011 | 330 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 301 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 1512 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 9 | 2008 | 7470 | 0.120 |
Why?
|
| Geriatrics | 1 | 1999 | 394 | 0.120 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 972 | 0.110 |
Why?
|
| Pharmacists | 5 | 2003 | 261 | 0.110 |
Why?
|
| Dextropropoxyphene | 4 | 1993 | 26 | 0.110 |
Why?
|
| Mediastinitis | 1 | 2013 | 49 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 14163 | 0.110 |
Why?
|
| Decision Making | 7 | 2018 | 3952 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 8052 | 0.110 |
Why?
|
| Child, Preschool | 18 | 2016 | 42665 | 0.110 |
Why?
|
| Fluid Therapy | 2 | 1996 | 587 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 806 | 0.110 |
Why?
|
| Residence Characteristics | 4 | 2018 | 2118 | 0.110 |
Why?
|
| Hormones | 1 | 1997 | 866 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2015 | 246 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 1661 | 0.110 |
Why?
|
| Competitive Medical Plans | 1 | 2013 | 26 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2015 | 347 | 0.110 |
Why?
|
| Administration, Inhalation | 2 | 2015 | 1169 | 0.100 |
Why?
|
| Odds Ratio | 6 | 2021 | 9666 | 0.100 |
Why?
|
| Medicine | 1 | 2001 | 945 | 0.100 |
Why?
|
| Costs and Cost Analysis | 5 | 2007 | 1666 | 0.100 |
Why?
|
| Drugs, Generic | 1 | 2017 | 455 | 0.100 |
Why?
|
| Social Security | 1 | 2012 | 101 | 0.100 |
Why?
|
| Reye Syndrome | 1 | 1992 | 28 | 0.100 |
Why?
|
| Compensation and Redress | 1 | 2012 | 66 | 0.100 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1996 | 388 | 0.100 |
Why?
|
| Length of Stay | 6 | 2007 | 6495 | 0.100 |
Why?
|
| Communication | 4 | 2018 | 3904 | 0.100 |
Why?
|
| Hospital Costs | 2 | 2015 | 957 | 0.100 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 3237 | 0.100 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 6973 | 0.100 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 677 | 0.100 |
Why?
|
| Physicians, Family | 3 | 2004 | 349 | 0.100 |
Why?
|
| Substance-Related Disorders | 3 | 2004 | 4423 | 0.100 |
Why?
|
| Peer Review, Research | 1 | 1995 | 344 | 0.100 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2016 | 1188 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2009 | 2764 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2016 | 1947 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2017 | 1319 | 0.090 |
Why?
|
| Sex Factors | 9 | 2014 | 10627 | 0.090 |
Why?
|
| Prepaid Health Plans | 1 | 2010 | 9 | 0.090 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 4857 | 0.090 |
Why?
|
| Hospitalists | 2 | 2007 | 298 | 0.090 |
Why?
|
| Hospitals, Maternity | 1 | 2011 | 31 | 0.090 |
Why?
|
| Canada | 2 | 2008 | 2129 | 0.090 |
Why?
|
| Legislation, Medical | 1 | 2011 | 99 | 0.090 |
Why?
|
| Medicare Part B | 2 | 2001 | 116 | 0.090 |
Why?
|
| Comorbidity | 7 | 2014 | 10590 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2006 | 5182 | 0.090 |
Why?
|
| Antimanic Agents | 1 | 2014 | 524 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 1996 | 886 | 0.090 |
Why?
|
| International Classification of Diseases | 2 | 2014 | 936 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2010 | 24314 | 0.090 |
Why?
|
| Teaching | 1 | 1998 | 1171 | 0.090 |
Why?
|
| Infection Control | 2 | 2015 | 985 | 0.090 |
Why?
|
| Diffusion of Innovation | 2 | 2012 | 724 | 0.090 |
Why?
|
| Population Surveillance | 3 | 2018 | 2594 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2012 | 291 | 0.080 |
Why?
|
| Oxycodone | 2 | 2008 | 144 | 0.080 |
Why?
|
| Patient Admission | 3 | 2013 | 1365 | 0.080 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 2429 | 0.080 |
Why?
|
| Child Behavior | 1 | 2015 | 864 | 0.080 |
Why?
|
| Insurance Benefits | 1 | 2011 | 185 | 0.080 |
Why?
|
| Time | 2 | 2018 | 552 | 0.080 |
Why?
|
| Survivors | 3 | 2011 | 2381 | 0.080 |
Why?
|
| Databases as Topic | 2 | 2009 | 472 | 0.080 |
Why?
|
| Preventive Health Services | 2 | 2011 | 570 | 0.080 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 26375 | 0.080 |
Why?
|
| Attitude to Health | 3 | 2007 | 2024 | 0.080 |
Why?
|
| Coronary Disease | 2 | 2001 | 5919 | 0.080 |
Why?
|
| Breast | 1 | 1998 | 1976 | 0.080 |
Why?
|
| Social Class | 3 | 2013 | 2007 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 3553 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 209 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 3 | 2015 | 1191 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 2 | 2006 | 112 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 788 | 0.070 |
Why?
|
| Publishing | 1 | 2015 | 837 | 0.070 |
Why?
|
| Respiratory Tract Infections | 2 | 2008 | 1014 | 0.070 |
Why?
|
| Drug and Narcotic Control | 2 | 2001 | 145 | 0.070 |
Why?
|
| Mammography | 2 | 2018 | 2433 | 0.070 |
Why?
|
| Developing Countries | 2 | 2001 | 2913 | 0.070 |
Why?
|
| Lidocaine | 3 | 2001 | 546 | 0.070 |
Why?
|
| Postal Service | 1 | 2008 | 96 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 780 | 0.070 |
Why?
|
| Perphenazine | 1 | 2007 | 33 | 0.070 |
Why?
|
| Insurance, Hospitalization | 1 | 2007 | 30 | 0.070 |
Why?
|
| Marketing of Health Services | 1 | 2008 | 151 | 0.070 |
Why?
|
| Occult Blood | 3 | 2016 | 199 | 0.070 |
Why?
|
| Health Literacy | 1 | 2013 | 466 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 646 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 1805 | 0.070 |
Why?
|
| Boston | 6 | 2004 | 9368 | 0.070 |
Why?
|
| Cardiology | 1 | 1998 | 1702 | 0.070 |
Why?
|
| Carcinoma | 1 | 1998 | 2330 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2001 | 775 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2013 | 848 | 0.070 |
Why?
|
| Fibrinolytic Agents | 4 | 2000 | 2080 | 0.070 |
Why?
|
| Washington | 2 | 2004 | 315 | 0.070 |
Why?
|
| Breast Feeding | 3 | 2004 | 1363 | 0.070 |
Why?
|
| Sulfamethoxazole | 1 | 2006 | 50 | 0.070 |
Why?
|
| Hospitals, Teaching | 4 | 2002 | 1157 | 0.070 |
Why?
|
| Antidiarrheals | 2 | 1996 | 46 | 0.070 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 951 | 0.070 |
Why?
|
| Depression, Postpartum | 1 | 2011 | 355 | 0.060 |
Why?
|
| Metronidazole | 2 | 2006 | 236 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2006 | 1326 | 0.060 |
Why?
|
| Fluconazole | 1 | 2006 | 156 | 0.060 |
Why?
|
| Chlorpromazine | 1 | 2005 | 111 | 0.060 |
Why?
|
| Demography | 2 | 2006 | 1641 | 0.060 |
Why?
|
| Online Systems | 1 | 2006 | 182 | 0.060 |
Why?
|
| Therapeutic Equivalency | 2 | 2002 | 134 | 0.060 |
Why?
|
| Computer User Training | 1 | 2004 | 19 | 0.060 |
Why?
|
| Infant | 10 | 2015 | 36534 | 0.060 |
Why?
|
| Quality Improvement | 3 | 2015 | 3855 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2009 | 730 | 0.060 |
Why?
|
| Episode of Care | 1 | 2005 | 127 | 0.060 |
Why?
|
| Feedback, Psychological | 1 | 2005 | 97 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2008 | 830 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 2191 | 0.060 |
Why?
|
| Crisis Intervention | 1 | 2005 | 111 | 0.060 |
Why?
|
| Oregon | 1 | 2004 | 149 | 0.060 |
Why?
|
| Psychometrics | 2 | 2008 | 3062 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2005 | 284 | 0.060 |
Why?
|
| Patient Participation | 3 | 2010 | 1446 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1546 | 0.060 |
Why?
|
| Attitude to Computers | 1 | 2005 | 196 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2013 | 5366 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2009 | 1003 | 0.060 |
Why?
|
| Sampling Studies | 2 | 2008 | 615 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2002 | 10098 | 0.050 |
Why?
|
| Haloperidol | 1 | 2005 | 394 | 0.050 |
Why?
|
| Follow-Up Studies | 11 | 2012 | 39345 | 0.050 |
Why?
|
| Patient Discharge | 4 | 2007 | 3476 | 0.050 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 70 | 0.050 |
Why?
|
| Morale | 1 | 1983 | 13 | 0.050 |
Why?
|
| Hospitals, Community | 2 | 1998 | 364 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6517 | 0.050 |
Why?
|
| Fever | 2 | 2010 | 1613 | 0.050 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2003 | 41 | 0.050 |
Why?
|
| Treatment Outcome | 10 | 2018 | 65364 | 0.050 |
Why?
|
| Risperidone | 1 | 2005 | 383 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2011 | 1162 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 338 | 0.050 |
Why?
|
| Physician-Patient Relations | 4 | 2008 | 3269 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3433 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 1406 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2015 | 26420 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2007 | 4055 | 0.050 |
Why?
|
| Data Collection | 5 | 2008 | 3326 | 0.050 |
Why?
|
| Insurance, Medigap | 1 | 2001 | 20 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2006 | 551 | 0.050 |
Why?
|
| Retirement | 1 | 1983 | 198 | 0.050 |
Why?
|
| Risk | 2 | 2007 | 9609 | 0.050 |
Why?
|
| Pharmacoepidemiology | 2 | 2003 | 351 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1419 | 0.050 |
Why?
|
| Least-Squares Analysis | 2 | 1993 | 367 | 0.050 |
Why?
|
| Interprofessional Relations | 3 | 1998 | 997 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 182 | 0.050 |
Why?
|
| Peptic Ulcer | 2 | 2003 | 214 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 264 | 0.050 |
Why?
|
| State Government | 1 | 2004 | 388 | 0.040 |
Why?
|
| Drugs, Essential | 1 | 2001 | 71 | 0.040 |
Why?
|
| Geriatric Assessment | 2 | 2007 | 1422 | 0.040 |
Why?
|
| Mastectomy | 2 | 2000 | 1861 | 0.040 |
Why?
|
| Cost Savings | 3 | 2004 | 904 | 0.040 |
Why?
|
| Health | 1 | 1983 | 398 | 0.040 |
Why?
|
| Colonoscopy | 3 | 2016 | 1409 | 0.040 |
Why?
|
| Outpatients | 1 | 2007 | 1600 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2003 | 472 | 0.040 |
Why?
|
| Diarrhea | 2 | 1996 | 1320 | 0.040 |
Why?
|
| Incidence | 5 | 2010 | 21532 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2006 | 1003 | 0.040 |
Why?
|
| Nicardipine | 1 | 1999 | 59 | 0.040 |
Why?
|
| Pain | 2 | 2006 | 5100 | 0.040 |
Why?
|
| Alendronate | 1 | 2000 | 174 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2001 | 1736 | 0.040 |
Why?
|
| Diltiazem | 1 | 1999 | 132 | 0.040 |
Why?
|
| Nifedipine | 1 | 1999 | 221 | 0.040 |
Why?
|
| Risk Factors | 11 | 2021 | 74936 | 0.040 |
Why?
|
| Verapamil | 1 | 1999 | 242 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2210 | 0.040 |
Why?
|
| Povidone | 1 | 1978 | 31 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 6314 | 0.040 |
Why?
|
| Procaine | 1 | 1978 | 60 | 0.040 |
Why?
|
| Manitoba | 1 | 2017 | 24 | 0.040 |
Why?
|
| Pravastatin | 1 | 2000 | 393 | 0.040 |
Why?
|
| Industry | 3 | 1995 | 362 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2002 | 631 | 0.040 |
Why?
|
| Vaccination | 1 | 2010 | 3437 | 0.040 |
Why?
|
| Horses | 1 | 2018 | 294 | 0.040 |
Why?
|
| Television | 1 | 2000 | 410 | 0.040 |
Why?
|
| Aftercare | 1 | 2003 | 916 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1999 | 392 | 0.030 |
Why?
|
| Kenya | 2 | 1996 | 757 | 0.030 |
Why?
|
| Employment | 1 | 1983 | 1110 | 0.030 |
Why?
|
| Education, Pharmacy | 1 | 1996 | 38 | 0.030 |
Why?
|
| Biopsy | 2 | 2019 | 6786 | 0.030 |
Why?
|
| Neoplasms | 3 | 2017 | 22365 | 0.030 |
Why?
|
| Sigmoid Neoplasms | 1 | 1976 | 54 | 0.030 |
Why?
|
| Persuasive Communication | 1 | 1996 | 58 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2000 | 771 | 0.030 |
Why?
|
| Soil | 1 | 2016 | 120 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2008 | 2043 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1980 | 594 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 664 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2001 | 781 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 1999 | 498 | 0.030 |
Why?
|
| Reference Values | 3 | 2010 | 4938 | 0.030 |
Why?
|
| Mesentery | 1 | 1976 | 202 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 1997 | 445 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2000 | 570 | 0.030 |
Why?
|
| Plants, Toxic | 1 | 1995 | 70 | 0.030 |
Why?
|
| Home Infusion Therapy | 1 | 1995 | 18 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2000 | 556 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2001 | 849 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2011 | 8540 | 0.030 |
Why?
|
| Cephalexin | 2 | 1986 | 37 | 0.030 |
Why?
|
| Rural Health | 1 | 1996 | 302 | 0.030 |
Why?
|
| Motivation | 3 | 1996 | 2020 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 1207 | 0.030 |
Why?
|
| Arm | 1 | 1978 | 591 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2009 | 4030 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 2 | 2003 | 836 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1976 | 287 | 0.030 |
Why?
|
| Axilla | 1 | 1997 | 623 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 1997 | 362 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1998 | 476 | 0.030 |
Why?
|
| Patient Selection | 3 | 2002 | 4258 | 0.030 |
Why?
|
| Disclosure | 1 | 2000 | 755 | 0.030 |
Why?
|
| Urban Health | 1 | 1996 | 534 | 0.030 |
Why?
|
| Tolmetin | 1 | 1993 | 24 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2008 | 5107 | 0.030 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1993 | 55 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2013 | 52 | 0.030 |
Why?
|
| Child Welfare | 2 | 2010 | 522 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2006 | 3467 | 0.030 |
Why?
|
| Economic Recession | 1 | 2014 | 79 | 0.030 |
Why?
|
| Informed Consent | 1 | 2000 | 1010 | 0.030 |
Why?
|
| Inservice Training | 1 | 1996 | 375 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1980 | 806 | 0.030 |
Why?
|
| Tobramycin | 1 | 1993 | 65 | 0.030 |
Why?
|
| Education, Medical | 1 | 1985 | 1742 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2002 | 1874 | 0.030 |
Why?
|
| Information Services | 1 | 1994 | 239 | 0.030 |
Why?
|
| Prejudice | 1 | 1997 | 574 | 0.030 |
Why?
|
| Prospective Payment System | 1 | 2013 | 134 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 11221 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2533 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 1993 | 158 | 0.030 |
Why?
|
| Factor VIII | 1 | 1995 | 349 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 1023 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2863 | 0.030 |
Why?
|
| Patient Transfer | 1 | 1999 | 790 | 0.030 |
Why?
|
| Consumer Organizations | 1 | 1992 | 10 | 0.030 |
Why?
|
| California | 1 | 2016 | 1438 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1998 | 1269 | 0.020 |
Why?
|
| Norway | 1 | 2013 | 500 | 0.020 |
Why?
|
| Clindamycin | 2 | 1989 | 138 | 0.020 |
Why?
|
| Utilization Review | 1 | 2013 | 381 | 0.020 |
Why?
|
| Asia | 1 | 2013 | 629 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2018 | 3573 | 0.020 |
Why?
|
| Hemophilia A | 1 | 1995 | 359 | 0.020 |
Why?
|
| Community Health Services | 1 | 1996 | 659 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 2 | 2002 | 88 | 0.020 |
Why?
|
| Feedback | 2 | 2000 | 798 | 0.020 |
Why?
|
| Hospital Mortality | 2 | 2002 | 5349 | 0.020 |
Why?
|
| Internal Medicine | 1 | 1998 | 1064 | 0.020 |
Why?
|
| Anxiety | 1 | 2006 | 4672 | 0.020 |
Why?
|
| Office Visits | 2 | 2005 | 595 | 0.020 |
Why?
|
| Public Policy | 1 | 1995 | 552 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 2204 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2000 | 1605 | 0.020 |
Why?
|
| Probability | 2 | 2008 | 2479 | 0.020 |
Why?
|
| Nursing Staff | 1 | 1991 | 113 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1145 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2013 | 215 | 0.020 |
Why?
|
| Politics | 1 | 1997 | 822 | 0.020 |
Why?
|
| Premedication | 1 | 1990 | 245 | 0.020 |
Why?
|
| Continuity of Patient Care | 2 | 2011 | 1078 | 0.020 |
Why?
|
| Blood Banks | 1 | 1990 | 108 | 0.020 |
Why?
|
| Teaching Materials | 1 | 1990 | 85 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2010 | 105 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1980 | 1481 | 0.020 |
Why?
|
| Self Care | 1 | 1995 | 799 | 0.020 |
Why?
|
| Deinstitutionalization | 1 | 1989 | 19 | 0.020 |
Why?
|
| Intermediate Care Facilities | 1 | 1988 | 12 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2276 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 2000 | 3619 | 0.020 |
Why?
|
| Analgesia | 1 | 1993 | 460 | 0.020 |
Why?
|
| Nonodontogenic Cysts | 1 | 1968 | 5 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2010 | 228 | 0.020 |
Why?
|
| Maxillary Diseases | 1 | 1968 | 46 | 0.020 |
Why?
|
| Hyperglycemia | 2 | 2010 | 1388 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2871 | 0.020 |
Why?
|
| Biomedical Research | 3 | 2000 | 3463 | 0.020 |
Why?
|
| Postmenopause | 1 | 1997 | 2518 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2018 | 54924 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2008 | 150 | 0.020 |
Why?
|
| Enema | 1 | 2008 | 141 | 0.020 |
Why?
|
| Peer Group | 2 | 2005 | 702 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 548 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2010 | 585 | 0.020 |
Why?
|
| Organizational Innovation | 2 | 2004 | 540 | 0.020 |
Why?
|
| Comprehension | 1 | 2013 | 639 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2011 | 22287 | 0.020 |
Why?
|
| Stroke | 2 | 2006 | 9755 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 48 | 0.020 |
Why?
|
| Analgesics | 1 | 1993 | 1071 | 0.020 |
Why?
|
| Health Behavior | 1 | 2018 | 2650 | 0.020 |
Why?
|
| Vermont | 1 | 1986 | 80 | 0.020 |
Why?
|
| Arkansas | 1 | 1986 | 59 | 0.020 |
Why?
|
| Blood Donors | 1 | 1988 | 343 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 804 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1999 | 6411 | 0.020 |
Why?
|
| District of Columbia | 1 | 1986 | 159 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 4818 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 1218 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2007 | 506 | 0.020 |
Why?
|
| Korea | 1 | 2005 | 97 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1997 | 3472 | 0.020 |
Why?
|
| Professional Competence | 1 | 1989 | 430 | 0.020 |
Why?
|
| Patient Care Planning | 2 | 2007 | 905 | 0.020 |
Why?
|
| Bacteremia | 1 | 2012 | 986 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15442 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2008 | 505 | 0.020 |
Why?
|
| General Surgery | 2 | 2000 | 1720 | 0.010 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 428 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3435 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2005 | 5952 | 0.010 |
Why?
|
| Morbidity | 1 | 2010 | 1754 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 968 | 0.010 |
Why?
|
| Methadone | 1 | 2006 | 317 | 0.010 |
Why?
|
| Papaverine | 1 | 1983 | 45 | 0.010 |
Why?
|
| Gastric Acid | 1 | 2003 | 98 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2008 | 1760 | 0.010 |
Why?
|
| Forecasting | 1 | 1993 | 2945 | 0.010 |
Why?
|
| Propensity Score | 1 | 2011 | 1970 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 651 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1363 | 0.010 |
Why?
|
| Infant Food | 1 | 2003 | 139 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 2396 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1993 | 2783 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 973 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1988 | 966 | 0.010 |
Why?
|
| Benzene | 2 | 1953 | 106 | 0.010 |
Why?
|
| Patients | 1 | 1989 | 908 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 658 | 0.010 |
Why?
|
| Group Practice, Prepaid | 1 | 2001 | 15 | 0.010 |
Why?
|
| Insulin | 2 | 2007 | 6606 | 0.010 |
Why?
|
| Family | 1 | 2013 | 3210 | 0.010 |
Why?
|
| Accidental Falls | 1 | 2010 | 1080 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1932 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1980 | 5196 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1990 | 6228 | 0.010 |
Why?
|
| Poisoning | 2 | 1953 | 252 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1142 | 0.010 |
Why?
|
| National Health Programs | 1 | 2004 | 442 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 368 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 1300 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 352 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 592 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 202 | 0.010 |
Why?
|
| Steroids | 1 | 2004 | 938 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1980 | 384 | 0.010 |
Why?
|
| Hospital Bed Capacity | 1 | 2000 | 202 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2004 | 969 | 0.010 |
Why?
|
| Prognosis | 3 | 2011 | 29979 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8535 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1983 | 990 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1983 | 643 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1978 | 5861 | 0.010 |
Why?
|
| Stress, Psychological | 2 | 1991 | 4530 | 0.010 |
Why?
|
| Patient Readmission | 2 | 2002 | 3288 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 490 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 496 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15944 | 0.010 |
Why?
|
| Inpatients | 1 | 1989 | 2570 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 472 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 929 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 682 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4628 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2000 | 427 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12828 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1956 | 42 | 0.010 |
Why?
|
| Panniculitis, Nodular Nonsuppurative | 1 | 1976 | 7 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1978 | 686 | 0.010 |
Why?
|
| Occupational Health | 2 | 1953 | 812 | 0.010 |
Why?
|
| Indonesia | 1 | 1996 | 131 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 659 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3251 | 0.010 |
Why?
|
| Purpura | 1 | 1956 | 117 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3414 | 0.010 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1956 | 131 | 0.010 |
Why?
|
| Psychiatry | 1 | 2007 | 1716 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2000 | 974 | 0.010 |
Why?
|
| Workload | 1 | 2000 | 849 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 10757 | 0.010 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1994 | 86 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2000 | 15660 | 0.010 |
Why?
|
| Education, Nursing, Continuing | 1 | 1992 | 69 | 0.010 |
Why?
|
| Geriatric Psychiatry | 1 | 1992 | 70 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5884 | 0.010 |
Why?
|
| Microcomputers | 1 | 1992 | 139 | 0.010 |
Why?
|
| Education, Continuing | 1 | 1992 | 115 | 0.010 |
Why?
|
| Mental Processes | 1 | 1992 | 246 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1990 | 36 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 7241 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1991 | 315 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2819 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 13053 | 0.000 |
Why?
|
| Behavior Control | 1 | 1988 | 46 | 0.000 |
Why?
|
| Pregnancy | 1 | 2011 | 30260 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1956 | 1179 | 0.000 |
Why?
|
| Parents | 1 | 2002 | 3595 | 0.000 |
Why?
|
| Behavioral Research | 1 | 1988 | 52 | 0.000 |
Why?
|
| Mentally Ill Persons | 1 | 1988 | 125 | 0.000 |
Why?
|
| Cefazolin | 1 | 1988 | 94 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 1625 | 0.000 |
Why?
|
| Information Systems | 1 | 1989 | 400 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1994 | 1542 | 0.000 |
Why?
|
| Facial Injuries | 1 | 1968 | 190 | 0.000 |
Why?
|
| Professional Practice | 1 | 1989 | 314 | 0.000 |
Why?
|
| Marriage | 1 | 1988 | 351 | 0.000 |
Why?
|
| Animals | 1 | 2018 | 169222 | 0.000 |
Why?
|
| Placebos | 1 | 1989 | 1667 | 0.000 |
Why?
|
| Documentation | 1 | 1990 | 917 | 0.000 |
Why?
|
| Research | 1 | 1992 | 1979 | 0.000 |
Why?
|
| Registries | 1 | 1999 | 8377 | 0.000 |
Why?
|
| Cesarean Section | 1 | 1990 | 1425 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1397 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1976 | 13000 | 0.000 |
Why?
|
| Sexual Behavior | 1 | 1988 | 2197 | 0.000 |
Why?
|
| Athletic Injuries | 1 | 1968 | 1245 | 0.000 |
Why?
|
| Software | 1 | 1992 | 4478 | 0.000 |
Why?
|
| Radiography | 1 | 1968 | 6983 | 0.000 |
Why?
|
| Inflammation | 1 | 1976 | 10871 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1988 | 8740 | 0.000 |
Why?
|
| Quality of Life | 1 | 1995 | 13489 | 0.000 |
Why?
|